Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13018528 | 0.85 | FGFR3 (0.32) | MYCPRMT5WDR77XDHABCG2 | |
| SCHEMBL4526795 | 0.83 | MYC (0.39) | MYCPRMT5WDR77PARP14PDE4A | |
| SCHEMBL741908 | 0.81 | PRMT5 (0.38) | MYCPRMT5WDR77PARP14PDE4A | |
| SCHEMBL2020180 | 0.79 | MYC (0.41) | MYCPRMT5WDR77PARP14PDE4A | |
| SCHEMBL10646424 | 0.78 | MYC (0.36) | MYCPRMT5WDR77PARP14RECQL | |
| SCHEMBL741483 | 0.76 | — | — | |
| SCHEMBL454924 | 0.76 | RECQL (0.52) | MYCPRMT5WDR77PARP14PDE4A | |
| SCHEMBL5509083 | 0.75 | HSD17B10 (0.45) | — | |
| SCHEMBL10992432 | 0.74 | HSD17B10 (0.47) | — | |
| SCHEMBL7694745 | 0.74 | HSD17B10 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP2C9, QDPR | MYC 3167/4885PRMT5 2900/4885WDR77 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.